STOCK TITAN

STAAR Surgical (NASDAQ: STAA) investor Yunqi Capital urges no vote on Alcon deal

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
PX14A6G

Rhea-AI Filing Summary

Yunqi Capital Limited, a 5.1% shareholder of STAAR Surgical Company, is urging fellow shareholders to vote against the proposed merger with Alcon at $30.75 per share. In a detailed letter, Yunqi expresses agreement with Glass Lewis’s recommendation against the deal and notes that, although ISS now supports the transaction, ISS also stated it would not be unreasonable for shareholders to oppose it.

Yunqi questions the robustness of STAAR’s go-shop process, pointing to the emergence of a well-known potential buyer during the go-shop that it believes could have bid higher and to STAAR’s subsequent handling of that party. The firm argues STAAR’s core fundamentals remain strong despite possible leadership changes, citing proprietary ICL technology, global distribution, and growth in key markets.

Yunqi highlights China as a key opportunity, noting better-than-expected recent sales trends and the planned January 2026 launch of the EVO ICL V5 line, which it says is expected to carry an approximately 30-70% price premium to existing ICLs. Yunqi plans to vote its own shares against the amended merger agreement and encourages shareholders to support STAAR’s standalone trajectory.

Positive

  • None.

Negative

  • None.

Insights

Activist STAAR holder opposes the Alcon sale, emphasizing process concerns and standalone upside.

Yunqi Capital, holding 5.1% of STAAR Surgical, is using an exempt solicitation to publicly oppose the proposed acquisition by Alcon at $30.75 per share. The letter positions Yunqi alongside Glass Lewis, which continues to recommend against the deal, while acknowledging that ISS has shifted to support the transaction but stated it would still be reasonable for shareholders to oppose it.

The firm questions the effectiveness of STAAR’s go-shop, referencing the appearance of a well-known potential buyer during the process and the company’s communication about this party. These points are framed as Yunqi’s views on whether shareholder value is best served by terminating the agreement and running a broader strategic review later, rather than accepting the current Alcon offer.

Yunqi also stresses its constructive outlook on STAAR’s standalone prospects, especially in China. It cites better-than-expected recent sales trends and the scheduled January 2026 launch of the EVO ICL V5 product, which it says is expected to carry an approximately 30-70% price premium versus existing ICLs. Overall, this communication may influence sentiment and the eventual merger vote, but it reflects one shareholder’s analysis and preferences rather than a finalized corporate outcome.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

NOTICE OF EXEMPT SOLICITATION

Submitted Pursuant to Rule 14a-6(g)

 

(Amendment No. _)

 

 

 

1. Name of the Registrant:

 

STAAR SURGICAL CO

 

2. Name of Person Relying on Exemption:

 

Yunqi Capital Limited

 

3. Address of Person Relying on Exemption:

 

Unit 3703, 37/F, AIA Tower, 183 Electric Road, North Point, Hong Kong

 

4. Written Materials. The following written material is attached hereto:

 

Press release, dated December 17, 2025, attached hereto as Exhibit 1.

 

* * *

 

Written material is submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934, as amended. This is not a solicitation of authority to vote any proxy. Yunqi Capital Limited (together with its affiliates, “Yunqi Capital”) is not asking for your proxy card and will not accept proxy cards if sent. The cost of this filing is being borne entirely by Yunqi Capital.

 

PLEASE NOTE: Yunqi Capital is not asking for your proxy card and cannot accept your proxy card. Please DO NOT send us your proxy card.

 

(Written material follows on next page)

 

 

 

 

Exhibit 1

  

Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory

 

HONG KONG, December 17, 2025 – Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today released the following letter to STAAR shareholders in response to the updated reports of Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) regarding the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (SIX/NYSE: ALC).

 

The text of the letter is as follows:

 

December 17, 2025

 

Dear Fellow STAAR Shareholders:

 

Following our review of the updated reports of the proxy advisory services ISS and Glass Lewis, Yunqi Capital remains opposed to STAAR’s proposed merger with Alcon, even at the revised offer price of $30.75.

 

We agree with the continued, strong recommendation of Glass Lewis against the merger, as well as with the extensive rationale for Glass Lewis’s opposition set forth in its most recently updated report. While we disagree with ISS’s recent decision to change its recommendation in favor of the proposed transaction, we underscore that ISS also observed that “it would not necessarily be unreasonable for a shareholder to remain opposed to this transaction.”1

 

Recent events indicate shareholder value will be maximized if the Company terminates the current agreement and initiates a normal strategic alternatives review in the future.

 

When first announcing the conclusion of the go-shop period in a press release, STAAR did not inform shareholders about the appearance, during the go-shop period, of a well-known, credible potential buyer with the capital, industry expertise, buyout experience, and interest to acquire STAAR at a higher price. We are not taking issue with whether STAAR should have disclosed this in its first press release; we are simply highlighting that the third party emerged.

 

 

1Permission to use quotes was neither sought nor obtained.

 

 

 

 

STAAR then updated shareholders about the appearance of this new third party after questions were raised by other stockholders. When finally acknowledging the appearance of this third party in a second, follow-up press release, STAAR claimed that the potential buyer did not contact STAAR until the beginning of the third week of the go-shop period. STAAR related this claim as if it should be taken to undercut the credibility and meaningfulness of the third party’s outreach.

 

But STAAR’s confirmation of the third-party outreach illustrates the insufficiency of STAAR’s go-shop process.

 

STAAR had told shareholders in its first press release following the go-shop period, that it had solicited acquisition proposals from a “wide range of potentially interested third parties,” yet it missed a well-known and credible party, which also happens to have extensive experience and presence in Asia. STAAR then chose to name this third party in the same follow-up press release, in an unconventional manner. That appears to have chased away the third party, at least for the time being.

 

While the Company states that it engaged with 21 third parties, we believe there are far more than 21 potentially interested strategic and financial parties globally. We suspect that this third party and others like it will continue to be in the market in the future.

 

The Prospects for the Business Are Strong, in Spite of Leadership Changes that May Come

 

We were encouraged to see that ISS expressed well-founded skepticism about STAAR management’s pessimistic outlook for the future of the business. ISS stated that “shareholders continue to have a reason to question whether the board’s messaging about downside risk from an operational perspective is completely credible.”

 

We disagree with ISS on its primary basis for its change in recommendation. In reaching its conclusion, ISS focused on a concern that, if shareholders reject the transaction, “shareholders would need to be concerned about next steps for STAA,” since “shareholders cannot rely on the incumbent leadership team.”

 

Our view is that while leadership changes may follow a failed merger vote, the fundamentals of STAAR’s business remain firmly intact. In the near term, STAAR shareholders require continuity of operations and stewardship of the business while the Board recalibrates leadership at the senior level. The core drivers of STAAR’s value—its proprietary ICL technology, established global distribution infrastructure, and deep penetration in key growth markets—are unchanged. Moreover, the relevant economic data and market indicators underpinning the Company’s valuation point to solid and accelerating demand for ICL procedures, reinforcing our view that STAAR’s standalone prospects remain strong and continue to improve.

 

 

 

 

We also view positively STAAR management’s recent comments regarding, in their words, “downward” sales trends in China during the fourth quarter of 2025. Sales trends in the last quarter were already materially better than our expectations. Looking ahead, STAAR China is scheduled to launch the differentiated EVO ICL V5 product line in January 2026. In advance of this launch, we would expect distributors to reduce existing inventories in order to mitigate obsolescence risk and free up capital to support purchases of the new product, which would be priced at an approximately 30-70% premium to the existing line of ICLs, according to our on-the-ground research. This increase in blended average selling price provides an exciting sales driver for 2026 and is under-appreciated by the market.

 

This momentum in STAAR’s business should not be transferred to Alcon at substantially less than fair value simply because the Company may undertake leadership changes following this failed process. Alcon shareholders should not receive the benefit of this upside in place of STAAR’s long-term and loyal shareholders who understand this business and appreciate its value.

 

We will continue to vote our shares against the amended merger agreement, and we urge all shareholders to do the same and to continue to have confidence in the standalone prospects for STAAR.

 

Sincerely,

 

Christopher M. Wang

Founder and Chief Investment Officer

Yunqi Capital Limited

 

About Yunqi Capital

 

Yunqi Capital is a Hong Kong headquartered investment manager with over US$250 million in assets under management. The firm deploys a fundamental long-short equity strategy, with a concentrated portfolio, that is primarily invested in the equity securities of companies with a significant China connection. Yunqi Capital is led by CIO Chris Wang, an experienced portfolio manager with a strong track record of generating attractive returns on capital, controlling portfolio risk and managing investment teams.

 

Disclaimers

 

THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. DO NOT SEND US YOUR PROXY CARD OR OTHER VOTING INSTRUCTION FORM. YUNQI CAPITAL IS NOT ASKING FOR YOUR PROXY AND WILL NOT ACCEPT PROXY CARDS IF SENT. YUNQI CAPITAL IS NOT ABLE TO VOTE YOUR PROXY, NOR DOES THIS COMMUNICATION CONTEMPLATE SUCH AN EVENT.

 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. This press release does not recommend the purchase or sale of a security. There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. In addition, this press release and the discussions and opinions herein are for general information only, and are not intended to provide investment advice.

 

 

 

 

The information contained or referenced herein is for information purposes only in order to provide the views of Yunqi Capital and the matters which Yunqi Capital believes to be of concern to stockholders described herein. The information is not tailored to specific investment objectives, the financial situations, suitability, or particular need of any specific person(s) who may receive the information, and should not be taken as advice in considering the merits of any investment decision. The views expressed herein represent the views and opinions of Yunqi Capital, whose opinions may change at any time and which are based on analyses of Yunqi Capital and its advisors. In addition, the information contained herein is being publicly disclosed without prejudice and shall not be construed to prejudice any of Yunqi Capital’s rights, demands, grounds and/or remedies under any contract and/or law.

 

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “in our view”, “from our perspective”, “intends”, “estimates”, “plans”, “will be”, “would” and similar expressions. Although Yunqi Capital believes that the expectations reflected in forward-looking statements contained herein are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties—many of which are difficult to predict and are generally beyond the control of Yunqi Capital or the Company—that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, the foregoing considerations and any other publicly stated risks and uncertainties should be read in conjunction with the risks and cautionary statements discussed or identified in the Company’s public filings with the U.S. Securities and Exchange Commission, including those listed under “Risk Factors” in annual reports on Form 10-K and quarterly reports on Form 10-Q and those related to the pending transaction involving the Company. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Yunqi Capital does not undertake any obligation to update or revise any forward-looking information or statements. Certain information included in this material is based on data obtained from sources considered to be reliable. Any analyses provided to assist the recipient of this material in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should not be viewed as factual and should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and, unless required by law, are subject to revision without notice.

 

Funds and investment vehicles (collectively, the “Yunqi Funds”) managed or advised by Yunqi Capital currently beneficially own shares of the Company. The Yunqi Funds are in the business of trading (i.e., buying and selling) securities and intend to continue trading in the securities of the Company. You should assume the Yunqi Funds will from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares. Consequently, Yunqi Capital’s beneficial ownership of shares of, and/or economic interest in, the Company may vary over time depending on various factors, with or without regard to Yunqi Capital’s views of the pending transaction or the Company’s business, prospects, or valuations (including the market price of the Company shares), including, without limitation, other investment opportunities available to Yunqi Capital, concentration of positions in the portfolios managed by Yunqi Capital, conditions in the securities markets, and general economic and industry conditions. Without limiting the generality of the foregoing, in the event of a change in the Company’s share price on or following the date hereof, the Yunqi Funds may buy additional shares or sell all or a portion of their holdings of the Company (including, in each case, by trading in options, puts, calls, swaps, or other derivative instruments). Yunqi Capital also reserves the right to change the opinions expressed herein and its intentions with respect to its investments in the Company, and to take any actions with respect to its investments in the Company as it may deem appropriate, and disclaims any obligation to notify the market or any other party of any such changes or actions, except as required by law.

 

Contact

 

Chris Wang
cwang@yunqipath.com

 

 

 

 

About Yunqi Capital

 

Yunqi Capital is a Hong Kong headquartered investment manager with over US$250 million in assets under management. The firm deploys a fundamental long-short equity strategy, with a concentrated portfolio, that is primarily invested in the equity securities of companies with a significant China connection. Yunqi Capital is led by CIO Chris Wang, an experienced portfolio manager with a strong track record of generating attractive returns on capital, controlling portfolio risk and managing investment teams.

 

Disclaimers

 

THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. DO NOT SEND US YOUR PROXY CARD OR OTHER VOTING INSTRUCTION FORM. YUNQI CAPITAL IS NOT ASKING FOR YOUR PROXY AND WILL NOT ACCEPT PROXY CARDS IF SENT. YUNQI CAPITAL IS NOT ABLE TO VOTE YOUR PROXY, NOR DOES THIS COMMUNICATION CONTEMPLATE SUCH AN EVENT.

 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. This press release does not recommend the purchase or sale of a security. There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. In addition, this press release and the discussions and opinions herein are for general information only, and are not intended to provide investment advice.

 

The information contained or referenced herein is for information purposes only in order to provide the views of Yunqi Capital and the matters which Yunqi Capital believes to be of concern to stockholders described herein. The information is not tailored to specific investment objectives, the financial situations, suitability, or particular need of any specific person(s) who may receive the information, and should not be taken as advice in considering the merits of any investment decision. The views expressed herein represent the views and opinions of Yunqi Capital, whose opinions may change at any time and which are based on analyses of Yunqi Capital and its advisors. In addition, the information contained herein is being publicly disclosed without prejudice and shall not be construed to prejudice any of Yunqi Capital’s rights, demands, grounds and/or remedies under any contract and/or law. This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “in our view”, “from our perspective”, “intends”, “estimates”, “plans”, “will be”, “would” and similar expressions. Although Yunqi Capital believes that the expectations reflected in forward-looking statements contained herein are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties—many of which are difficult to predict and are generally beyond the control of Yunqi Capital or the Company—that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, the foregoing considerations and any other publicly stated risks and uncertainties should be read in conjunction with the risks and cautionary statements discussed or identified in the Company’s public filings with the U.S. Securities and Exchange Commission, including those listed under “Risk Factors” in annual reports on Form 10-K and quarterly reports on Form 10-Q and those related to the pending transaction involving the Company. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Yunqi Capital does not undertake any obligation to update or revise any forward-looking information or statements. Certain information included in this material is based on data obtained from sources considered to be reliable. Any analyses provided to assist the recipient of this material in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should not be viewed as factual and should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and, unless required by law, are subject to revision without notice.

 

 

 

 

Funds and investment vehicles (collectively, the “Yunqi Funds”) managed or advised by Yunqi Capital currently beneficially own shares of the Company. The Yunqi Funds are in the business of trading (i.e., buying and selling) securities and intend to continue trading in the securities of the Company. You should assume the Yunqi Funds will from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares. Consequently, Yunqi Capital’s beneficial ownership of shares of, and/or economic interest in, the Company may vary over time depending on various factors, with or without regard to Yunqi Capital’s views of the pending transaction or the Company’s business, prospects, or valuations (including the market price of the Company shares), including, without limitation, other investment opportunities available to Yunqi Capital, concentration of positions in the portfolios managed by Yunqi Capital, conditions in the securities markets, and general economic and industry conditions. Without limiting the generality of the foregoing, in the event of a change in the Company’s share price on or following the date hereof, the Yunqi Funds may buy additional shares or sell all or a portion of their holdings of the Company (including, in each case, by trading in options, puts, calls, swaps, or other derivative instruments). Yunqi Capital also reserves the right to change the opinions expressed herein and its intentions with respect to its investments in the Company, and to take any actions with respect to its investments in the Company as it may deem appropriate, and disclaims any obligation to notify the market or any other party of any such changes or actions, except as required by law.

 

Contact

 

Chris Wang
cwang@yunqipath.com

 

 

FAQ

What is Yunqi Capital’s position on the proposed STAAR (STAA) merger with Alcon?

Yunqi Capital states that it remains opposed to STAAR Surgical’s proposed merger with Alcon, even at the revised offer price of $30.75 per share, and says it will vote its shares against the amended merger agreement.

How much STAAR Surgical (STAA) stock does Yunqi Capital own?

Yunqi Capital describes itself as a 5.1% shareholder of STAAR Surgical Company, holding this stake through funds and vehicles it manages or advises.

How do ISS and Glass Lewis differ on the STAAR–Alcon transaction?

Yunqi notes that Glass Lewis continues to recommend against the merger and provides extensive rationale in its latest report, while ISS recently changed its recommendation in favor of the deal but also commented that it would not necessarily be unreasonable for a shareholder to remain opposed.

Why does Yunqi Capital question STAAR’s go-shop process in the Alcon deal?

Yunqi points to the emergence of a well-known, credible potential buyer during the go-shop period that it believes could have paid more, and to the way STAAR communicated about this third party, as reasons it views the go-shop process as insufficient. These points are presented as Yunqi’s opinions about the sale process.

What standalone growth drivers at STAAR Surgical does Yunqi Capital emphasize?

Yunqi highlights STAAR’s proprietary ICL technology, global distribution infrastructure, and penetration in key growth markets as core value drivers, and cites economic and market data it believes support solid and accelerating demand for ICL procedures.

What opportunity does Yunqi Capital see in STAAR’s China business and EVO ICL V5?

Yunqi references STAAR management’s comments about “downward” Q4 2025 China sales trends but says those trends were materially better than its expectations. It notes that STAAR China is scheduled to launch the EVO ICL V5 line in January 2026, which Yunqi expects to be priced at an approximately 30-70% premium to existing ICLs, viewing this as an important driver for 2026 sales.

Is Yunqi Capital soliciting proxies from STAAR (STAA) shareholders?

No. The communication repeatedly states that it is not a solicitation of authority to vote any proxy. Yunqi Capital says it is not asking for proxy cards, will not accept them if sent, and is not able to vote shareholders’ proxies.

Staar Surg

NASDAQ:STAA

STAA Rankings

STAA Latest News

STAA Latest SEC Filings

STAA Stock Data

1.16B
49.50M
0.56%
111.03%
8.06%
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States
MONROVIA